Analysts Set Expectations for AQST FY2024 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for Aquestive Therapeutics in a report released on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will post earnings per share of ($0.45) for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.47) per share.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm earned ($0.03) EPS.

A number of other research analysts also recently commented on AQST. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, November 6th. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Finally, Leerink Partners upped their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $3.64 on Thursday. The stock has a market cap of $331.89 million, a PE ratio of -8.09 and a beta of 2.62. The stock’s fifty day moving average is $4.74 and its two-hundred day moving average is $4.06. Aquestive Therapeutics has a 1-year low of $1.84 and a 1-year high of $6.23.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of AQST. Victory Capital Management Inc. acquired a new position in shares of Aquestive Therapeutics in the 2nd quarter valued at $27,000. nVerses Capital LLC acquired a new position in Aquestive Therapeutics in the third quarter valued at $28,000. The Manufacturers Life Insurance Company acquired a new position in Aquestive Therapeutics in the second quarter valued at $76,000. Financial Advocates Investment Management raised its holdings in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after buying an additional 14,000 shares during the last quarter. Finally, Harvey Capital Management Inc. purchased a new position in shares of Aquestive Therapeutics during the third quarter worth about $88,000. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.